Latest News
Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours
...
Lineage Launches Phase 2a Study by Genentech of RG6501 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
28 November 2022 - - US-based biotechnology company Lineage Cell Therapeutics, Inc's (NYSE American) (TASE: LCTX) partner Genentech, a member of Switzerland's Roche Group, has launched a Phase 2a, multicenter, open-label, sin...
Anteris Technologies Receives FDA Clearance to Initiate Early Feasibility Study for its Novel TAVR Product, DurAVR
28 November 2022 - - The US Food and Drug Administration has conditionally approved Australia-based structural heart company Anteris Technologies Ltd's (ASX: AVR) DurAVR Transcatheter Heart Valve (THV; TAVR) System for investigational device exe...
Perspectum, Nuance Collaborate to Scale Access to AI-Enabled Integrated Digital Care Platforms to Improve Patient Care for Metabolic Disease
28 November 2022 - - US-based medical technology company Perspectum and Nuance Communications, Inc., a Microsoft company have forged collaboration to deliver at scale Perspectum's integrated digital platform suite for metabolic disease...
ICPO Foundation, PreMIT Enter Strategic Partnership to Develop a Network of Precision Oncology and Theranostic Centers
28 November 2022 - - Germany-based The International Centers for Precision Oncology Foundation and Australia-based PreMIT Pty Ltd (PreMIT), have forged a collaboration to develop a global network of Precision Oncology and Theranostics centers, the pr...